Drug interactions
Lorlatinib + Paclitaxel
Severity: Minor
Lorlatinib and Paclitaxel: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib is a CYP3A4 inducer and may lower paclitaxel exposure, though CYP2C8 is the main paclitaxel pathway. The clinical effect is uncertain.
What this interaction means in plain words
Lorlatinib and Paclitaxel have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Lorlatinib belongs to Oncology; Paclitaxel belongs to Oncology.
Why it happens
Lorlatinib induces CYP3A4, which may modestly increase paclitaxel metabolism.
What to do
No routine adjustment; monitor tumor response and toxicity.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Paclitaxel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Paclitaxel
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Frequently asked questions
Can I take Lorlatinib with Paclitaxel?
MediHelp rates the interaction as minor. Lorlatinib and Paclitaxel have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Lorlatinib is a CYP3A4 inducer and may lower paclitaxel exposure, though CYP2C8 is the main paclitaxel pathway. The clinical effect is uncertain.
How serious is the interaction between Lorlatinib and Paclitaxel?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine adjustment; monitor tumor response and toxicity.
What other medicines interact with Paclitaxel?
MediHelp also lists interactions of Paclitaxel with, for example, Adenovirus types 4 and 7 live, Cobicistat, Cyclosporin. The full list is on the Paclitaxel page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
